查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1873163

全球生物製药安全性检测市场

Biologics Safety Testing
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球生物製药安全检测市场预计2030年将达到130亿美元

2024年全球生物製药安全检测市场规模估计为66亿美元，预计到2030年将达到130亿美元，在分析期间（2024-2030年）内复合年增长率（CAGR）为11.8%。本报告分析的细分市场之一—残留宿主细胞蛋白和DNA检测，预计将以12.9%的复合年增长率成长，并在分析期结束时达到58亿美元。霉浆菌检测细分市场预计在分析期间将以10.1%的复合年增长率成长。

美国市场规模估计为18亿美元，而中国市场预计将以11.1%的复合年增长率成长。

预计2024年，美国生物製药安全检测市场规模将达18亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到20亿美元，在2024年至2030年的分析期间内，复合年增长率（CAGR）将达到11.1%。其他值得关注的区域市场分析包括日本和加拿大，预计在分析期间内，这两个国家的复合年增长率将分别达到10.4%和9.8%。在欧洲，德国预计将以约8.6%的复合年增长率成长。

全球生技药品安全检测市场－主要市场趋势与驱动因素概述

为什么生技药品安全性测试是生物製药研发的基石

生物製剂安全测试是生物製药研发的基石，旨在确保疫苗、单株抗体、基因疗法和细胞疗法等复杂生物製药的安全性。与传统化学药物不同，生物製剂生物来源，其复杂的结构和潜在的免疫反应使其面临独特的挑战。安全性测试包括全面的检测，以检测可能损害产品安全性的污染物，例如病毒、霉浆菌和内毒素。此外，宿主细胞蛋白 (HCP) 污染的检测也至关重要，因为生产细胞株中残留的蛋白质可能引发有害的免疫反应。这些严格的测试旨在满足美国食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 等监管机构制定的高安全标准。生物製药安全性测试对于保护公众健康、确保生物製药的安全性和有效性至关重要。

法规要求如何影响生物製药安全性测试？

监管要求是推动生物製药安全检测发展的根本动力，它规定了确保生物製药符合严格安全和品质标准的方法和技术。美国食品药物管理局 (FDA)、欧洲药品管理局 (EMA) 和世界卫生组织 (WHO) 等国际组织已製定了全面的指南，明确规定了所需的安全检测、检测频率和可接受的污染阈值。对于希望将生物製药推向市场的公司而言，遵守这些法规至关重要；不遵守法规可能导致严重的延误、产品召回，甚至被完全拒收。随着生物製药的复杂性日益增加，监管标准也日趋严格，推动了次世代定序(NGS) 和质谱等先进检测技术的应用。这些方法具有更高的灵敏度和特异性，能够侦测到微量污染物。不断变化的监管环境持续促进生物製药安全检测的创新，确保该行业始终能够应对不断涌现的安全挑战。

哪些创新正在改变生物製药安全性测试？

近年来，技术进步重塑了生物製药安全性检测领域，显着提高了检测程序的准确性、灵敏度和效率。高通量筛检(HTS) 技术是其中最具影响力的进步之一，它能够快速检测大量样本，从而缩短生物製药的研发週期。同时，基于细胞的检测方法也在加速应用，与传统的体外方法相比，这些方法能够提供更具相关性的生理数据。这些检测方法对于在研发早期阶段检测潜在的免疫抗原性和细胞毒性至关重要，能够更深入地了解生物製药的安全性。人工智慧 (AI) 和机器学习也发挥着重要作用，它们增强了数据分析能力，能够更准确地识别模式和预测结果。此外，新型生物感测器和微流体平台的出现，促进了即时现场检测，并实现了对生物製药生产过程中的持续监测。这些技术进步不仅提高了安全性检测的可靠性，还有助于提高工作流程效率并降低整体成本，从而使生物製药的研发过程更有效率。

哪些因素推动了生物製药安全检测市场的快速成长？

生物製药安全检测市场的成长受多种因素驱动。其中一个关键驱动因素是生物製药产业本身的快速发展，这得益于对包括个人化医疗和免疫疗法最先进治疗的需求不断增长。随着生物製药开发平臺的不断扩展，对全面安全检测的需求日益增加，促使生物製药公司加强对先进检测技术的投资。此外，生物相似药（与已获核准产品高度相似的生物製剂）的日益普及，也使得人们更加关注安全检测，以确保这些产品符合等效性和安全标准。监管机构透过实施更严格的安全检测要求，要求进行更频繁、更严谨的检测，在推动市场成长方面也发挥关键作用。将自动化、人工智慧和次世代定序引入安全检测通讯协定，透过提高效率和准确性，进一步促进了市场扩张。最后，生物製药产业的全球化正在推动各地区安全标准的协调统一，从而增加了对标准化和可靠检测方法的需求。这些因素共同推动了生物製药安全检测市场的强劲成长。

部分：

细分市场（服务、试剂盒和试剂、设备）、检测类型（残留宿主细胞蛋白和DNA检测、霉浆菌检测、无菌检测、内毒素检测、其他检测）、应用领域（单株抗体生产、疫苗生产、血液和血液製品生产、细胞和基因治疗产品生产、其他应用）

受访公司范例

  • Avance Biosciences Inc.
  • Charles River Laboratories International, Inc.
  • Cytovance Biologics
  • Eurofins Scientific SE
  • Lonza Group AG
  • Merck KgaA
  • Pace Analytical Services, Inc.
  • Sartorius AG
  • SGS SA
  • Source BioScience PLC
  • Thermo Fisher Scientific, Inc.
  • Toxikon Corporation
  • WuXi AppTec

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，革新市场和竞争情报分析。

与典型的LLM或产业专用的SLM方法不同，Global Industry Analysts建立了一个由世界各地领域专家精心策划的内容库，包括影片转录、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

我们最新发布的报告纳入了关税对区域市场的影响，正如全球产业分析师预测的那样，关税将改变企业的竞争地位，而企业的竞争地位将取决于其总部所在地、製造地以及进出口（成品和OEM产品）。这种复杂多变的市场现实将透过微观和宏观市场动态影响竞争对手，包括销货成本增加、盈利下降以及供应链重组。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 世界其他地区

第四章 竞赛

简介目录
Product Code: MCP10720

Global Biologics Safety Testing Market to Reach US$13.0 Billion by 2030

The global market for Biologics Safety Testing estimated at US$6.6 Billion in the year 2024, is expected to reach US$13.0 Billion by 2030, growing at a CAGR of 11.8% over the analysis period 2024-2030. Residual Host-Cell Proteins & DNA Detection Tests, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$5.8 Billion by the end of the analysis period. Growth in the Mycoplasma Tests segment is estimated at 10.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 11.1% CAGR

The Biologics Safety Testing market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.4% and 9.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.6% CAGR.

Global Biologics Safety Testing Market - Key Trends and Drivers Summarized

What Makes Biologics Safety Testing a Pillar of Biopharmaceutical Development?

Biologics safety testing stands as a fundamental pillar in the development of biopharmaceuticals, ensuring that complex biological products, including vaccines, monoclonal antibodies, gene therapies, and cell-based treatments, are safe for patient use. Unlike traditional chemical drugs, biologics are derived from living organisms, presenting unique challenges due to their intricate structures and potential to trigger immune responses. Safety testing involves a comprehensive array of assays aimed at detecting contaminants such as viruses, mycoplasma, and endotoxins that could compromise the product's safety. Additionally, testing for host cell protein (HCP) contamination is crucial since residual proteins from production cell lines can provoke adverse immune reactions. The stringent nature of these tests is driven by the need to meet the high safety standards set by regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The critical importance of biologics safety testing lies in its ability to safeguard public health and ensure that biologics are both safe and effective.

How Do Regulatory Requirements Influence Biologics Safety Testing?

Regulatory requirements are a driving force behind the evolution of biologics safety testing, dictating the methods and technologies used to ensure that biologic products meet stringent safety and quality standards. International bodies such as the FDA, EMA, and World Health Organization (WHO) have established comprehensive guidelines that specify the necessary safety tests, the frequency of these tests, and acceptable contamination thresholds. Compliance with these regulations is essential for companies aiming to bring biologics to market, as non-compliance can lead to significant delays, recalls, or outright rejection of a product. Over time, as biologics have become more complex, regulatory standards have become more rigorous, pushing the adoption of advanced testing techniques like next-generation sequencing (NGS) and mass spectrometry. These methods offer heightened sensitivity and specificity, capable of detecting even minute levels of contaminants. The constantly evolving regulatory landscape continues to drive innovation in biologics safety testing, ensuring that the industry remains equipped to address emerging safety challenges.

Which Technological Innovations Are Transforming Biologics Safety Testing?

Recent technological innovations are reshaping the field of biologics safety testing, leading to significant improvements in the accuracy, sensitivity, and efficiency of testing procedures. High-throughput screening (HTS) technologies represent one of the most impactful advancements, enabling the rapid testing of large sample volumes, thus accelerating the development timeline for biologics. Concurrently, the adoption of cell-based assays has gained momentum, providing more relevant physiological data compared to traditional in vitro methods. These assays are crucial for detecting potential immunogenicity and cytotoxicity early in the development process, offering deeper insights into the safety profile of biologics. Artificial intelligence (AI) and machine learning are also making their mark by enhancing data analysis capabilities, allowing for more precise identification of patterns and prediction of outcomes. Moreover, the advent of novel biosensors and microfluidic platforms has facilitated real-time, on-site testing, enabling continuous monitoring of biologics during production. These technological advancements are not only enhancing the reliability of safety testing but also streamlining workflows and reducing overall costs, making the biologics development process more efficient and effective.

What’s Driving the Rapid Growth in the Biologics Safety Testing Market?

The growth in the biologics safety testing market is driven by several factors. A primary driver is the rapid growth of the biologics sector itself, fueled by the increasing demand for cutting-edge therapies, including personalized medicine and immunotherapies. As the pipeline of biologics continues to expand, there is a heightened need for comprehensive safety testing, prompting biopharmaceutical companies to invest heavily in advanced testing technologies. Additionally, the rising prevalence of biosimilars-biologics that are highly similar to already approved products-has intensified the focus on safety testing to ensure these products meet equivalency and safety standards. Regulatory agencies have also played a significant role in this market growth by imposing more stringent safety testing requirements, necessitating more frequent and rigorous testing. The incorporation of automation, artificial intelligence, and next-generation sequencing into safety testing protocols has further propelled market expansion by enhancing efficiency and accuracy. Lastly, the globalization of the biopharmaceutical industry has led to increased efforts to harmonize safety standards across different regions, driving demand for standardized and reliable testing methods. These factors collectively are fueling the robust growth of the biologics safety testing market.

SCOPE OF STUDY:

The report analyzes the Biologics Safety Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Segment (Services, Kits & Reagents, Instruments); Test Type (Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests, Other Tests); Application (Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 13 Featured) -

  • Avance Biosciences Inc.
  • Charles River Laboratories International, Inc.
  • Cytovance Biologics
  • Eurofins Scientific SE
  • Lonza Group AG
  • Merck KgaA
  • Pace Analytical Services, Inc.
  • Sartorius AG
  • SGS SA
  • Source BioScience PLC
  • Thermo Fisher Scientific, Inc.
  • Toxikon Corporation
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Biologics Safety Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Stringency in Regulatory Requirements Propels Market Growth for Biologics Safety Testing
    • Advancements in Analytical Technologies Strengthen the Business Case for Enhanced Safety Testing
    • Surging Demand for Biologics and Biosimilars Generates Accelerated Need for Comprehensive Safety Testing
    • Technological Innovations in Rapid Testing Methods Drive Adoption Across Biopharma Companies
    • Regulatory Compliance Standards Throw the Spotlight on the Critical Importance of Safety Testing in Biologics Development
    • Expanding Biologics Pipeline Spurs Growth in the Safety Testing Market
    • Rising Incidence of Biologic Contamination Issues Sustains Demand for Rigorous Testing Protocols
    • Increasing Focus on Patient Safety and Product Quality Drives Adoption of Advanced Biologics Safety Testing Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Monoclonal Antibody Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Monoclonal Antibody Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Monoclonal Antibody Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Vaccine Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Vaccine Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Vaccine Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Blood & Blood Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Blood & Blood Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Blood & Blood Product Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cellular & Gene Therapy Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cellular & Gene Therapy Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Cellular & Gene Therapy Product Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Residual Host-Cell Proteins & DNA Detection Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Residual Host-Cell Proteins & DNA Detection Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Residual Host-Cell Proteins & DNA Detection Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Mycoplasma Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Mycoplasma Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Mycoplasma Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Sterility Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Sterility Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Sterility Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Endotoxin Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Endotoxin Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Endotoxin Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 39: World 15-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 40: World Biologics Safety Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Biologics Safety Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Biologics Safety Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Biologics Safety Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • JAPAN
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • CHINA
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • EUROPE
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Biologics Safety Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Biologics Safety Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • GERMANY
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of World 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of World 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of World Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of World Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of World 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030

IV. COMPETITION